NDC 70022-001 - buprenorphine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70022-001
- Package NDCs from labels
- 70022-001-10
- Manufacturer
- PAYLESS COMPOUNDERS, LLC
- Effective date
- 2024-12-11
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| buprenorphine - PAYLESS COMPOUNDERS, LLC | PAYLESS COMPOUNDERS, LLC | 2024-12-11 | ANIMAL COMPOUNDED DRUG LABEL |
| buprenorphine - PAYLESS COMPOUNDERS, LLC | PAYLESS COMPOUNDERS, LLC | 2015-10-29 | ANIMAL COMPOUNDED DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70022-001-10 | buprenorphine | 10 mL in 1 VIAL, MULTI-DOSE | INJECTION, SOLUTION | 10 | 10 | |
| 70022-001-10 | buprenorphine | 10 mL in 1 VIAL, MULTI-DOSE | INJECTION, SOLUTION | 10 | 3 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70022-001 | BUPRENORPHINE INJECTION, SOLUTION BUPRENORPHINE SOLUTION [PAYLESS COMPOUNDERS, LLC] | 10 | 1 package rows | 20241213_a1c1f498-e101-467f-b81c-1451c44e7a01.zip |
| 70022-001 | BUPRENORPHINE INJECTION, SOLUTION [PAYLESS COMPOUNDERS, LLC] | 3 | 1 package rows | 20151030_7fc0c3fd-5122-43ce-995d-a55a7ea02371.zip |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 99a5b62f-bc08-44f4-abb8-300520d2162a | 2026-03-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| 2-Pack Facial Serum | 2-PACK FACIAL SERUM | Guangzhou Ariel Biotech Co., Ltd. | 27c7f645-cfb3-6db1-e063-6394a90a42ff | 2026-03-06 | Warnings | 059QF0KO0R |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 8f2b94dc-f42f-45d5-8274-9e748ec20ef0 | 2026-03-05 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Walgreens Unscented Pain Relieving | LIDOCAINE HYDROCHLORIDE, BENZYL ALCOHOL | Walgreen Co. | 41eadb4f-2ca5-42a1-e063-6294a90ab4e2 | 2026-03-04 | Warnings | LKG8494WBH |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Major Pharmaceuticals | c5fbec69-e7de-44a8-b9fa-0378ae61a9fe | 2026-03-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride | BUPRENORPHINE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | 442831cf-9636-433a-9a12-e9a8cd31f72a | 2026-02-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | d5b011ef-f1be-47f2-8f8b-07553f36193c | 2026-02-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Kidnex IV | GINKGO BILOBA, ALPHA-KETOGLUTARICUM ACIDUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MALICUM ACIDUM, PYRUVIC ACID, SUCCINICUM ACIDUM, ARGENTUM METALLICUM, AURUM METALLICUM, CUPRUM METALLICUM, GERMANIUM SESQUIOXIDE, MERCURIUS VIVUS, NUX VOMICA, KIDNEY (SUIS), LYMPH NODE (SUIS), NAPHTHOCHINONUM, NATRUM OXALACETICUM, PHOSPHORUS, URINARY BLADDER (SUIS), ACONITICUM ACIDUM, CIS- | Energique, Inc. | 23de6b8e-7622-4ba6-89f7-37bd151687e2 | 2026-02-26 | Warnings | XF417D3PSL |
| Tricitrates | TRICITRATES | Chartwell Governmental & Specialty RX, LLC. | c4ff0407-3930-4c48-afd4-d2cb3e1b18f4 | 2026-02-25 | Warnings, Adverse reactions | 1Q73Q2JULR |
| Leader Extra Strength Effervescent Antacid and Pain Reliever | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Cardinal Health | c5d7bf5f-3e59-52f2-e053-2a95a90a4a00 | 2026-02-25 | Warnings | XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 300ae3d0-464c-d0be-e063-6294a90a7f9d | 2026-02-21 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Unit Dose Solutions, Inc. | 4b301ad7-ac0e-f849-e063-6394a90a27d5 | 2026-02-19 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Mitochondria Pro | ARALIA QUINQUEFOLIA, ARNICA MONTANA, ADENOSINUM TRIPHOSPHORICUM DINATRUM, ALPHA-KETOGLUTARICUM ACIDUM, ASCORBICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, CALCAREA CARBONICA, CITRICUM ACIDUM, CUPRUM METALLICUM, CYSTEINUM, FERRUM METALLICUM, IODIUM, LEVOTHYROXINUM, MAGNESIUM GLUCONICUM DIHYDRICUM, MALICUM ACIDUM, MANGANUM ACETICUM, NADIDUM, NATRUM PYRUVICUM, NICOTINAMIDUM, PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, SELENIUM METALLICUM, SULPHUR, THIAMINUM HYDROCHLORICUM, UBIDECARENONUM, ZINCUM METALLICUM, | Energique, Inc. | 2f365207-b730-428d-9465-8853e86e79ff | 2026-02-18 | Warnings | XF417D3PSL |
| Buprenorphine | BUPRENORPHINE | Sun Pharmaceutical Industries, Inc. | 9fd1f18f-0b0f-4059-b603-19ecbf0ed63a | 2026-02-11 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Sun Pharmaceutical Industries, Inc. | 91b68606-05de-4586-ae31-07e8cc9160cf | 2026-02-10 | Warnings, Adverse reactions | 56W8MW3EN1 |
| BUPRENORPHINE | BUPRENORPHINE | A-S Medication Solutions | bfb02ea5-22f2-432e-afc8-f1dbe2ea0614 | 2026-02-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Actavis Pharma, Inc. | 6cccf229-9611-4b6f-8f1b-acc8ff1ed3f8 | 2026-02-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Amneal Pharmaceuticals LLC | 17b63f10-c9df-44be-80fa-6f1c305583b8 | 2026-02-02 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Camber Pharmaceuticals, Inc. | 221195e4-de08-414c-af08-a611a74789de | 2026-01-30 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID MONOHYDRATE | Atlantic Biologicals Corp. | 42d837ae-2578-46df-92d2-24774964aaad | 2026-01-28 | Adverse reactions | 1Q73Q2JULR XF417D3PSL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.